Alzheimer's disease: Visual system review

Optometry

Volumn 81, Issue 1, 2010, Pages 12-21

  Valenti, Denise A ^a  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

Author keywords

Aging; Alzheimer's disease; Amyloid; Cognition; Neurodegeneration; Optic nerve; Retina; Vision

Indexed keywords

AMYLOID;

ALZHEIMER DISEASE; ARTICLE; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; VISION; VISUAL DISORDER;

ALZHEIMER DISEASE; AMYLOID; HUMANS; RISK FACTORS; VISION DISORDERS; VISION, OCULAR;

EID: 71149116769     PISSN: 15291839     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.optm.2009.04.101     Document Type: Article

References (128)

1. Hebert L., Scherr P., Bieniasm J., et al. Alzheimer's disease in the us population: prevalence estimates using the 2000 census. Arch Neurol 60 (2003) 1119-1122
2. CDC. US deaths down sharply in 2006. In: Statistics NCH ed. Washington DC: Department of Health and Human Services, 2008. Available at: http://www.cdc.gov/media/pressrel/2008/r080611.htm.
3. Alzhiemer's. Alzheimer's disease facts and figures (2008) Comprehensive statistical abstract of U.S. data on Alzheimer's disease. Available at: http://alz.org/index.asp. Last accessed October 2009.
4. Lewin. Medicare and Medicaid costs for people with Alzheimer's disease. Washington, D.C. April 2001:1.
5. McKee A., Au R., Cabral H., et al. Visual association pathology in preclinical Alzheimer disease. J Neuropathol Exp Neurol 65 (2006) 621-630
6. Valenti DA. Anterior Visual System and circadian function with reference to Alzheimer's disease. In: Cronin-Golomb A, Hof PR, eds. Vision in Alzheimer's disease. Interdisciplinary Topics in Gerontology 2004;34:1-29.
7. Cronin-Golomb A., Rizzo J., Corkin S., et al. Visual function in Alzheimer's disease and normal aging. Ann NY Acad Sci 640 (1991) 28-35
8. Thiyagesh S.N., Farrow T.F.D., Parks R.W., et al. The neural basis of visuospatial perception in Alzheimer's disease and healthy elderly comparison subjects: an fMRI study. Psychiatry Res (2009) 172
9. Mapstone M., Dickerson K., and Duffy C.J. Distinct mechanisms of impairment in cognitive ageing and Alzheimer's disease. Brain 131 (2008) 1618-1629
10. Gilmore G.C., Wend H.E., Naylor L., et al. Motion perception and Alzheimer's disease. J Gerontol 49 (1994) P52-P57
11. Armstrong R. Visual field defects in Alzheimer's disease patients may reflect differential pathology in the primary visual cortex. Optom Vis Sci 73 (1996) 677-682
12. Trick G., Trick L., Morris P., et al. Visual field loss in senile dementia of the Alzheimer's type. Neurology 45 (1995) 68-74
13. Cronin-Golomb A., Sugiura R., Corkin S., et al. Incomplete achromatopsia in Alzheimer's disease. Neurobiol Aging 14 (1993) 471-477
14. Quigley H., Addicks E., and Green R. Optic nerve damage in human glaucoma III: quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic optic neuropathy, papilledema and toxic optic neuropathy. Arch Ophthalmol 100 (1982) 135-146
15. Pacheco-Cutillas M., Edgar D., and Sahriae A. Acquired colour vision defects in glaucoma-their detection and clinical significance. Br J Ophthalmol 83 (1999) 1396-1402
16. Shabana N., Cornilleau P., Carkeet A., and Ptk C. Motion perception in glaucoma patients: a review. Survey Ophthal 48 (2003) 92-106
17. Mei M., and Leat S. Suprathreshold contrast matching in maculopathy. Invest Ophthalmol Vis Sci (2007) 48
18. Feigl B., Brown B., Lovie-Kitchin J., et al. Monitoring retinal function in early age-related maculopathy: visual performance after one year. Eye 2005 19 (2005) 1169-1177
19. Ruppertsberg A., Wuerger S., and Bertamini M. When S-cones contribute to chromatic global motion processing. Vis Neurosci 24 (2007) 1-8
20. Bayer A., and Ferrari F. Severe progression of glaucomatous optic neuropathy in patients with Alzheimer's disease. Eye 16 (2002) 209-212
21. American Foundation for the Blind. Senior Site, Glaucoma Fact Sheet. Available at: http://www.afb.org/seniorsite.asp?SectionID=63&TopicID=286&DocumentID=3198. Last accessed October 2009.
22. National Institutes of Health. Fact Sheet, Glaucoma. Available at: http://www.nih.gov/about/researchresultsforthepublic/glaucoma.pdf. Last accessed October 2009.
23. National Institutes of Health. Prevalence of Blindness Data Tables (NEI Statistics and Data). Available at: http://www.nei.nih.gov/eyedata/pbd_tables.asp Last accessed August 2009.
24. Marshal E.C. Racial differences in the presentation of chronic open-angle glaucoma. J Am Optome Assoc 60 (1989) 760-767
25. Varma R., Ying Lai M., Francis B.A., et al. Prevalence of open angle glaucoma and ocular hypertension in Latinos. Ophthalmology 111 (2004) 1439-1448
26. Glaucoma Research Foundation. Glaucoma Research Foundation Facts and Stats. 2009. Available at: http://www.glaucoma.org/learn/glaucoma_facts.php. Last accessed October 2009.
27. Estermann S., Daepp G., Cattapan-Ludewig K., et al. Effect of oral donepezil on intraocular pressure in normotensive Alzheimer patients. J Ocul Pharmacol Ther 22 (2006) 62-67
28. Miki A. Protective effect of donepezil on retinal ganglion cells in vitro and in vivo. Curr Eye Res 31 (2006) 69-77
29. Rabins P.V., Blacker D., Rovner B.W., et al. APA Work Group on Alzheimer's Disease And Other Dementias. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Am J Psychiatry 164 (2007) 5-56
30. Goldblum D., Garweg J., and Bohnke M. Topical rivastigmine, a selective acetyclcholinesterase inhibitor, lowers intraocular pressure in rabbits. J Ocul Pharmacol Ther 1 (2000) 29-35
31. Molinuevo J., Llado A., and Rami L. Memantine: Targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. Am J Alzheimer Dis Dementias 2 (2005) 77-85
32. Reisberg B., Doody M.D., Stoffler A., et al. Memantine in moderate to severe Alzheimer's disease. N Eng J Med 348 (2003) 1333-1341
33. Tariot P.N., Falow M.R., Grossber G.T., et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 291 (2004) 317-324
34. Yucel Y.H., Gupta N., Zhang Q., et al. Memantine protects neurons from shrinkage in the lateral geniculate nucleus in experimental glaucoma. Arch Ophthalmol 124 (2006) 217-225
35. Weber A., Chen H., Hubbard W., et al. Experimental glaucoma and cell size, density and number in primate lateral geniculate nucleus. Invest Ophthalmol Vis Sci 41 (2000) 1370-1379
36. Yucel Y., Zhang Q., Weinreb R., et al. Atrophy of relay neurons in mango-and parvocellular layers in the lateral geniculate nucleus in experimental glaucoma. Invest Opthal Vis Sci 42 (2001) 3216-3222
37. Gupta N., Ang L., Noel deTilly L., et al. Human glaucoma and neural degeneration in intracranial optic nerve, lateral geniculate nucleus and visual cortex. Br J Ophthalmol 90 (2006) 674-678
38. Chaturvedi N., Hedley-Whyte T., and Dreyer E. Lateral geniculate nucleus in glaucoma. Am J Opthal 116 (1993) 182-188
39. Alexander K.R., Pokorny J., Smith V.C., et al. Contrast discrimination deficits in retinitis pigmentosa are greater for stimuli that favor the magnocellular pathway. Vis Res 41 (2001) 671-683
40. Hof P., and Morrison J. Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: II. Primary and secondary visual cortex. J Comp Neurol 301 (1990) 55-64
41. Leuba G., and Saini K. Pathology of subcortical visual centres in relation to cortical degeneration in Alzheimer's disease. Neuropathol Appl Neurobiol 21 (1995) 410-422
42. Buguet A., Py P., and Romanet J. 24-Hour (nyctohemeral) and sleep-related variations of intraocular pressure in healthy white individuals. Am J Opthalmol 117 (1994) 342-347
43. Sacca S., Rolando M., Marletta A., et al. Fluctuations of intraocular pressure during the day in open angle glaucoma, normal tension glaucoma and normal individuals. Opthalmoligica 212 (1998) 115-119
44. Little J., Saatlin A., Sunderland T., et al. Sundown syndrome in severely demented patients with probable Alzheimer's disease. J Geriatr Psychiatry Neurol 8 (1995) 103-106
45. Mirmiran M., Swaab D., Kok J., et al. Circadian rhythms and the suprachiasmatic nucleus in perinatal development, aging and Alzheimer's disease. Prog Brain Res 16 (1992) 151-162
46. Swaab D., Flilers E., and Partimann T. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res 342 (1985) 37-44
47. Bliwise D., Carroll J., Lee K., et al. Sleep and sundowning in nursing home patients with dementia. Psychiatr Res 48 (1993) 277-292
48. Wisor J., Edgar D., Yesavage J., et al. Sleep and circadian abnormalities in a transgenic mouse model of Alzheimer's disease: a role for cholinergic transmission. Neuroscience 131 (2005) 375-385
49. Zhang B., Veasey S., Wood M., et al. Impaired rapid eye movement sleep in the Tg2576 APP murine model of Alzheimer's disease with injury to pedunculopontine cholinergic neurons. Neurobiology 167 (2005) 1361-1369
50. Noel C., Kabo A., Romanet J., et al. Twenty-four hour time course of intraocular pressure in healthy and glaucomatous Africans: relation to sleep patterns. Ophthalmology 108 (2001) 139-144
51. Liu J., Kripke D., Hoffman R., et al. Elevation of human intraocular pressure at night under moderate illumination. Invest Ophthal Vis Sci 40 (1999) 2439-2442
52. Munch M., Kobialka S., Steiner R., et al. Wavelength dependent effects of evening light exposure on sleep architecture and sleep EEG power density in men. Physiol Regul Integr Comp Physiol 290 (2006) 1421-1428
53. Berson D., Dunn F., and Motoharu T. Phototransduction by retinal ganglion cells that set the circadian clock. Science 295 (2002) 1070-1073
54. Bayer A., Ferrari F., and Erb C. High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur Neurol 47 (2002) 165-168
55. Ou Y., Grossman D.S., Sloan F.A., et al. Assessing the relationship between open-angle glacouma and Alzheimer's disease. ARVO Annual Meeting Fort Lauderdale Florida (2009) 4086/A342
56. Tamura H., Kawakami H., Knamoto T., et al. High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. J Neuro Sci (2006) 65-67
57. Enzenauer R., and Bowers P. Angle-closure glaucoma after discontinuing donepezil hydrochloride (Aricept). J Gerontol A Biol Sci Med Sci 60 (2005) 1083
58. Ferrington D.A., Tran T.N., Lew K.L., et al. Different death stimuli evoke apoptosis via multiple pathways in retinal pigment epithelial cells. Exp Eye Res 83 (2006) 638-650
59. Sarraf D., Gin T., Yu F., et al. Long term drusen study. Retina 19 (1999) 513-519
60. Jonasson F., Arnarsson A., Sasaki H., et al. The prevalence of age related maculopathy in Iceland: Reykjavik eye study. Arch Ophthalmol 1 (2003) 379-385
61. Klein R., Meuer S., Knudison M., et al. The epidemiology of retinal reticular drusen. Am J Opthalmol 145(2) (2008) 317-326
62. AREDS. Cognitive impairment in the age related eye disease study. Arch Ophthalmol 124 (2006) 537-543
63. Luibl V., Isas J., Kayed R., et al. Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clin Invest 116 (2006) 378-385
64. Anderson D., Talaga K., Rivest A., et al. Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 78 (2004) 243-256
65. Yoshida T., Ohno-Matsui K., Ichinose S., et al. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J Clin Invest 115 (2005) 2793-2800
66. Dentchev T., Milan A., Lee V., et al. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Molecular Vis 9 (2003) 184-190
67. Luibl V., Isas J., Kayed R., et al. Drusen deposits associated with ging and age-related macular degeneration contain nonfibrillar amyloid oligomers. J Clini Invest 116 (2006) 378-385
68. Shahidi M., Shakoor A., Blair N., et al. A method for chorioretinal oxygen tension measurement. Curr Eye Res 31 (2006) 357-366
69. Delori F., Goger D., Hammond B., et al. Macular pigment density measured by autofluorescence spectrometry: comparison with feflectometry and heterochromatic flicker photometry. J Opt Soc Am A Opt Image Sci Vis 18 (2001) 1212-1230
70. Iseri P., Altinas O., Today T., et al. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer's disease. J Neuro-ophthalmol 26 (2006) 18-24
71. Blanks J., Torigoe Y., Hinton D., et al. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging (1996) 17
72. Dentchev T.M.A., Lee V.M., Trojanowski J.Q., et al. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Molecular Vis 9 (2003) 184-190
73. Thakkinstian A., Bowe S., McEvoy M., et al. Association between apolipoprotein E polymorphisms and age-related macular degeneration: A HuGE review and meta-analysis. Am J Epidemiol 9 (2008) 813-822
74. Malek G., Johnson L., Mace B., et al. Apolipoprotein E allele-dependent pathogenesis: A model for age-related retinal degeneration. PNAS 102 (2005) 11900-11905
75. Ding J.D., Lin J., Mace B.E., et al. Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amylid beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vis Res 3 (2007) 339-345
76. Goldstein L., Muffat J., Cherny R., et al. Cytosolic Beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet 361 (2003) 1258-1265
77. Ding D., Lin J., Mace B., et al. Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amylid beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vis Res (2007)
78. Melov S., Wolf N., Strozyk D., et al. Mice transgenic for Alzheimer disease beta amyloid develop lens cataracts that are rescued by antioxidant treatment. Free Radical Biology and Medicine 38 (2005) 258-261
79. Collinson D., Wang L., Wormston M., et al. Spatial characteristics of receptor-induced calcium signaling in human lens capsular bags. Invest Ophthal Vis Sci 45 (2004) 200-205
80. Sweeney M., Garland D., and Truscott R. Movement of cysteine in intact monkey lenses: the major site of entry is the germinative region. Exp Eye Res 77 (2003) 245-251
81. Thomas G., Williams M., Sanderson J., et al. The human lens possesses acetylcholine receptors that are functional throughout life. Exp Ey Res 64 (1997) 849-852
82. Shaffer R., and Hetherington J. Anticholinesterase drugs and cataracts. Am J Opthalmol 62 (1966) 613-618
83. DeRoetth A. Lenticular opacities in glaucoma patients receiving echothiophate iodide therapy. Am J Ophthalmol 62 (1966) 619-628
84. Albrecht M., and Barany E. Early lens changes in Macca fasciularis monkeys under topical treatment with echothiophate or carbachol studied by slit image photography. Invest Ophthal Vis Sci 18 (1979) 8
85. Durand G., Hubert M., Kuno H., et al. Muscarinic receptor antagonist-induced lenticular opacity in rats. Toxicological Sci 66 (2002) 166-172
86. Deroetth. Lenticular opacities in glaucoma patients receiving echothiophate iodide therapy. JAMA 195 (1966) 152-154
87. Firth J.M., Vucicevic Z.M., and Tsou K.C. The influence of miotics on the lens. Ann Ophthalmol 5 (1973) 685-690
88. Abraham S.V., and Teller J.J. Influence of various miotics on cataract formation. Br J Ophthalmol 53 (1969) 5
89. Gomez-Tortosa E., and Jimenz-Alfaro D. Pupil response to tropicamide in Alzheimer's disease and other neurodegenerative disorders. Acta Neurol Scand 94 (1996) 104-109
90. Scinto L., Rentz D., Potter H., et al. Pupil assay and Alzheimer's disease: a critical analysis. Neurology 52 (1999) 673-677
91. Reitner A., Baumgartner I., Thuile C., et al. The mydriatic effect of tropicamide and its diagnostic use in Alzheimer's disease. Vis Res 37 (1997) 165-168
92. Hanyu H., Hirao K., Shimizu S., et al. Phenylephrine and pilocarpine eye drop test for dementia with Lewy Bodies and Alzheimer's disease. Neurosci Letters 414 (2007) 174-177
93. Kaneyuki H., Mitsuno S., Nishida T., et al. Enhanced miotic response to topical dilute pilocarpine in patients with Alzheimer's disease. Neurology (1998) 1-2:802-4
94. Scinto L. Pupillary hypersensitivity predicts cognitive decline in community dwelling elders. Neurobiol Aging 29 (2008) 222-230
95. Fotiou D., Brozou C., Haidich A., et al. Pupil reaction to light in Alzheimer's disease: evaluation of pupil size changes and mobility. Aging Clin Exp Res 19 (2007) 364-371
96. Scinto L.F., Wu M., Daffner C.K., et al. Selective cell loss in Edinger-Westphal in asymptomatic elders and Alzheimer's patients. Neurobiol Aging 22 (2001) 729-736
97. Kaufman P. Enhancing trabecular outflow by disrupting the actin cytoskeleton, increasing uveoscleral outflow with prostaglandin and understanding the pathophysiology of presbyopia interrogating Mother Nature: asking why, asking how, recognizing the signs, following the trail. Exp Ey Res 86 (2008) 3-17
98. Yucel Y., Zhang Q., Qupta N., et al. Loss of neurons in magnocellular and parvocellular layers of the lateral geniculate nucleus in glaucoma. Arch Opthal 118 (2000) 378-384
99. Pietrini P., Furey M., Graff-Radford N., et al. Preferential metabolic involvement of visual cortical areas in a subtype of Alzheimer's disease: clinical implications. Am J Psychiatry 153 (1996) 1261-1268
100. Curcio C., and Drucker D. Retinal ganglion cells in Alzheimer's disease and aging. Ann Neurol 33 (1993) 248-257
101. Sadun A., and Bassi C. Optic nerve damage in Alzheimer's disease. Ophthalmology 97 (1990) 9-17
102. Hinton D., Sadun A., Blanks J., et al. Optic nerve degeneration in Alzheimer's disease. N Eng J Med 315 (1986) 485-487
103. Davies D.C., McCoubrie P., McDonald B., et al. Myelintated axon number in the optic nerve is unaffected by Alzheimer's disease. Br J Ophthalmol 79 (1995) 596-600
104. Tsai C., Ritch R., Schwartz B., et al. Optic nerve head and nerve fiber layer in Alzheimer's disease. Arch Opthalmol 109 (1991) 199-204
105. Hedges T., Galves R., Spiegelman D., et al. Retinal nerve fiber layer abnormalities in Alzheimer's disease. Acta Ophthlmol Scand 74 (1996) 271-275
106. Parisi V. Morphological and functional retinal impairment in Alzheimer's disease patients. Clin Neurophysiol 112 (2001) 1860-1867
107. Valenti D. Neuroimaging of retinal nerve fiber layer in AD using optical coherence tomography. Neurology 69 (2007) 1060
108. Bersisha F., Feke G.T., Trempe C.L., et al. Localized retinal nerve fiber layer thinning in patients with early glaucoma or Alzheimer's disease. ARVO Annual Meeting; Fort Lauderdale, Florida (2006) 3379/B912
109. Paquet C., Boissonnot M., Roger F., et al. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 420 (2007) 97-99
110. Mentis M., Horwitz B., Grady C., et al. Visual cortical dysfunction in Alzheimer's Disease evaluated with temporarily graded stress test during PET. Am J Psychiatry 153 (1996) 32-40
111. Mentis M., Alexander G., Krasuski J., et al. Increasing required neural response to expose abnormal brain function in mild versus moderate or sever Alzheimer's Disease: PET study using parametric visual stimulation. Am J Psychiatry 155 (1998) 785-794
112. Camicioli R., Bouchard T., and Licis L. Dual-tasks and walking fast: Relationship to extra-pyramidal signs in advanced Alzheimer disease. J Neurological Sci 3 (2006) 205-209
113. Lord S., and Dayhew J. Visual factors for falls in older people. J Am Geriatr Soc 49 (2001) 508-515
114. French D., Campbell R., Spehar A., et al. Drugs and falls in community dwelling older people: A National Veterans Study. Clin Therapeutics 28 (2006) 619-630
115. Valenti D. Vision assessment in neurodegenerative disease. American Public Health Association National Conference Philadelphia, PA 2005.
116. Tinnetti M., Baker D., and McAvay G. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Eng J Med 331 (1994) 821-827
117. Graafmans W., Ooms M., and Hofstee H. Falls in the elderly: a prospective study of risk factors and risk profiles. Am J Epidemiol 143 (1996) 1129-1136
118. Marottoli R., Berkman L., Leo-Summers L., et al. Predictors of mortality and institutionalization after hip fracture: the New Haven EPESE cohort. Established populations for epidemiologic studies of the elderly. Am J Public Health 84 (1994) 1807-1812
119. Fitzgerald J., Moore P., and Dittus R. The care of elderly patients with hip fracture. N Eng J Med 319 (1988) 241-244
120. Ivers R., Cumming R., Mitchell P., et al. Visual risk factors for hip fracture in older people. J Am Geriatr Soc 51 (2003) 356-363
121. Glynn R., Seddon J., and Drug J. Falls in elderly patients with glaucoma. Arch Ophthalmol 109 (1991) 205-210
122. Ivers R., Norton R., Cumming R., et al. Visual impairment and risk of hip fracture. Am J Epidemiol 152 (2000) 633-639
123. Lord S., and Menz H. Visual contributions to postural stability in older adults. Gerontology 46 (2000) 306-310
124. Anand V., Buckley J., Scally A., et al. Postural stability changes in the elderly with cataract simulation and refractive blur. Invest Ophthalmol Visi Sci 44 (2003) 4670-4675
125. Startzell J., Ownes D., Mulfinger L., et al. Stair negotiation in older people: a review. J Am Geriatr Soc 48 (2000) 567-580
126. Szylick JS, W Fishaman, GA, Alzexander KR, et al. Perceived and actual performance of daily tasks: relationship to visual function tests in individuals with retinitis pigmentosa. Ophthalmology 2001;108:65-67.
127. Johnson L., Buckley J.G., Scally A.J., et al. Multifocal spectacles increase variability in toe clearance and risk of tripping in the elderly. Invest Ophthal Vis Sci 48 (2006) 1466-1471
128. Lord S., Dayhew J., and Howland A. Multifocal glasses impair edge-contrast sensitivity and depth perception and increase the risk of falls in older people. J Am Geriatric Soc 50 (2002) 1760-1766